ENHANZE Expansion Halozyme’s ENHANZE technology is already deployed across five commercialized products in 100+ markets and is expanding through collaborations with Roche, Bristol Myers Squibb, Janssen, AbbVie, Lilly, and argenx. This presents a sales opportunity to partner with additional biopharma companies seeking subcutaneous delivery to improve patient experience and drive faster, broader market access.

Global partnerships The company revenue model relies on milestones and royalties from collaborations with leading pharma and biotech firms. This indicates strong cross-border and mega-therapy opportunities for subcutaneous formulations, enabling BD teams to target large, cash-rich partners for license expansions and new target programs.

Board and leadership momentum Recent board additions and veteran commercial leadership reintegration signal renewed focus on global rollout and commercialization strategy for ENHANZE, Hypercon, Aerocon, and auto-injector products. BD teams can leverage these moves to align co-marketing, territory expansion, and joint go-to-market plans with Halozyme’s leadership.

High growth signal Strong quarterly results with significant royalties and overall revenue nearing a billion dollars, coupled with double-digit year-over-year growth expectations, indicate a favorable market environment for partnerships, licensing deals, and expanded manufacturing or service arrangements to support scalable subcutaneous delivery programs.

Competitive positioning Halozyme faces competition in subcutaneous delivery from alternatives like rival platforms in regional markets (e.g., Alteogen in South Korea). This creates a sales angle to emphasize ENHANZE's mature global footprint, proven clinical and patient-outcome benefits, and established partner ecosystems when pursuing multinational or late-stage oncology and immunotherapy deals.